TY - JOUR
T1 - Association of Physical Activity With Primary Cardiac Arrest Risk in the General Population
T2 - A Nationwide Cohort Study of the Dose-Response Relationship
AU - Jin, Moo Nyun
AU - Yang, Pil Sung
AU - Yu, Hee Tae
AU - Kim, Tae Hoon
AU - Lee, Hye Young
AU - Sung, Jung Hoon
AU - Byun, Young Sup
AU - Joung, Boyoung
N1 - Publisher Copyright:
© 2021 Mayo Foundation for Medical Education and Research
PY - 2022/4
Y1 - 2022/4
N2 - Objective: To quantify the dose-response relationship between moderate to vigorous physical activity and primary cardiac arrest (PCA). Patients and Methods: There were 504,840 participants older than 18 years who underwent the Korean National Health Screening Program, including a self-administered questionnaire for physical activity from January 1, 2009, through December 31, 2014. Physical activity levels were converted into metabolic equivalent tasks (METs) per week and categorized to correspond with multiples of public health recommendations. We evaluated the quantitative and categorical dose-response relationship between physical activity and PCA. Results: A curvilinear dose-response relationship between physical activity and PCA was observed; the benefits started at two-thirds (5 MET-hour/week) of the United States and World Health Organization guidelines–recommended minimum (7.5 MET-hour/week) and continued to 5 times (40 MET-hour/week) the recommended minimum (P nonlinearity <.001). The largest benefit was noted at a level of 2 to 3 times the recommended minimum (hazard ratio, 0.6; 95% CI, 0.4 to 0.8). In addition, there was no evidence of an increased PCA risk at a level more than 5 times the recommended minimum (hazard ratio, 0.7; 95% CI, 0.5 to 1.1). These associations were consistent regardless of age, sex, body mass index, comorbid conditions, and estimated 10-year risk for cardiovascular disease. Conclusion: The beneficial effect of physical activity on PCA started at two-thirds of the recommended minimum and continued to 5 times the recommended minimum. No excess risk for PCA was present among individuals with activity levels more than 5 times the recommended minimum regardless of cardiovascular disease or lifestyle risk factor presence.
AB - Objective: To quantify the dose-response relationship between moderate to vigorous physical activity and primary cardiac arrest (PCA). Patients and Methods: There were 504,840 participants older than 18 years who underwent the Korean National Health Screening Program, including a self-administered questionnaire for physical activity from January 1, 2009, through December 31, 2014. Physical activity levels were converted into metabolic equivalent tasks (METs) per week and categorized to correspond with multiples of public health recommendations. We evaluated the quantitative and categorical dose-response relationship between physical activity and PCA. Results: A curvilinear dose-response relationship between physical activity and PCA was observed; the benefits started at two-thirds (5 MET-hour/week) of the United States and World Health Organization guidelines–recommended minimum (7.5 MET-hour/week) and continued to 5 times (40 MET-hour/week) the recommended minimum (P nonlinearity <.001). The largest benefit was noted at a level of 2 to 3 times the recommended minimum (hazard ratio, 0.6; 95% CI, 0.4 to 0.8). In addition, there was no evidence of an increased PCA risk at a level more than 5 times the recommended minimum (hazard ratio, 0.7; 95% CI, 0.5 to 1.1). These associations were consistent regardless of age, sex, body mass index, comorbid conditions, and estimated 10-year risk for cardiovascular disease. Conclusion: The beneficial effect of physical activity on PCA started at two-thirds of the recommended minimum and continued to 5 times the recommended minimum. No excess risk for PCA was present among individuals with activity levels more than 5 times the recommended minimum regardless of cardiovascular disease or lifestyle risk factor presence.
UR - http://www.scopus.com/inward/record.url?scp=85126269952&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2021.10.003
DO - 10.1016/j.mayocp.2021.10.003
M3 - Article
C2 - 35287954
AN - SCOPUS:85126269952
SN - 0025-6196
VL - 97
SP - 716
EP - 729
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 4
ER -